ArticleResearch square2026
Crimean-Congo hemorrhagic fever virus protein GP38 from isolate M18-China confers broad immunological breadth.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne, negative-strand RNA virus that causes outbreaks of lethal hemorrhagic fever. No approved vaccines or specific antiviral treatments are available. CCHFV glycoprotein GP38 is an integral component of the pre-fusion glycoprotein entry complex, plays roles in viral pathogenesis, and is a key target of antibody-mediated protection. Herein, we investigated the hypothesis that recombinant GP38 itself could elicit protection against divergent CCHFV isolates/strains in an animal model. Accordingly, we generated GP38 immunogens from six CCHFV clades and showed that GP38 from the isolate M18-China induces a broad immunological response in mice despite its lower amino acid sequence similarity to other isolates. We identified sequences in M18-China GP38 associated with this immunological breadth and evaluated it as a vaccine candidate. Although M18-China GP38 was not protective in isolation, our findings warrant further exploration of its utility as one component of a broadly protective CCHFV vaccine.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.